Download PDF
Thromb Haemost 2024; 124(03): 203-222
DOI: 10.1055/a-2211-5202
New Technologies, Diagnostic Tools and Drugs

Diphenyl-tetrazol-propanamide Derivatives Act as Dual-Specific Antagonists of Platelet CLEC-2 and Glycoprotein VI

Nobuo Watanabe 
1   Department of Emergency and Critical Care Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan
2   Institute of Advanced Biosciences, Tokai University, Hiratsuka, Kanagawa, Japan
,
Yoshiko Shinozaki
3   Support Center for Medical Research and Education, Tokai University, Isehara, Kanagawa, Japan
,
Sanae Ogiwara
3   Support Center for Medical Research and Education, Tokai University, Isehara, Kanagawa, Japan
,
Riko Miyagasako
3   Support Center for Medical Research and Education, Tokai University, Isehara, Kanagawa, Japan
,
Ayumi Sasaki
3   Support Center for Medical Research and Education, Tokai University, Isehara, Kanagawa, Japan
,
Junko Kato
3   Support Center for Medical Research and Education, Tokai University, Isehara, Kanagawa, Japan
,
Yusuke Suzuki
3   Support Center for Medical Research and Education, Tokai University, Isehara, Kanagawa, Japan
,
Natsuko Fukunishi
3   Support Center for Medical Research and Education, Tokai University, Isehara, Kanagawa, Japan
,
Yoshinori Okada
3   Support Center for Medical Research and Education, Tokai University, Isehara, Kanagawa, Japan
,
Takeshi Saito
1   Department of Emergency and Critical Care Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan
,
Yumi Iida
3   Support Center for Medical Research and Education, Tokai University, Isehara, Kanagawa, Japan
,
Misaki Higashiseto
3   Support Center for Medical Research and Education, Tokai University, Isehara, Kanagawa, Japan
,
Haruchika Masuda
4   Department of Physiology, Tokai University School of Medicine, Shimokasuya, Isehara, Kanagawa, Japan
,
Eiichiro Nagata
5   Department of Neurology, Tokai University School of Medicine, Isehara, Kanagawa, Japan
,
Kazuhito Gotoh
6   Department of Laboratory Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan
,
Mari Amino
1   Department of Emergency and Critical Care Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan
,
Tomoatsu Tsuji
1   Department of Emergency and Critical Care Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan
,
Seiji Morita
1   Department of Emergency and Critical Care Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan
,
Yoshihide Nakagawa
1   Department of Emergency and Critical Care Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan
,
Noriaki Hirayama
2   Institute of Advanced Biosciences, Tokai University, Hiratsuka, Kanagawa, Japan
7   The Institute of Medical Sciences, Tokai University, Isehara, Kanagawa, Japan
,
Sadaki Inokuchi 
1   Department of Emergency and Critical Care Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan
2   Institute of Advanced Biosciences, Tokai University, Hiratsuka, Kanagawa, Japan
› Author Affiliations Funding This work was supported by grants from the Institute of Advanced Biosciences of Tokai University (S.I. and N.W.) and a Grant-in-Aid for Scientific Research Category C (23K07490 to N.W.) and AMED (A369-TS; to N.W.).
› Further Information
    Permissions and Reprints


Abstract

Background Platelet C-type lectin-like receptor 2 (CLEC-2) induces platelet activation and aggregation after clustering by its ligand podoplanin (PDPN). PDPN, which is not normally expressed in cells in contact with blood flow, is induced in inflammatory immune cells and some malignant tumor cells, thereby increasing the risk of venous thromboembolism (VTE) and tumor metastasis. Therefore, small-molecule compounds that can interfere with the PDPN–CLEC-2 axis have the potential to become selective antiplatelet agents.

Methods and Results Using molecular docking analysis of CLEC-2 and a PDPN–CLEC-2 binding-inhibition assay, we identified a group of diphenyl-tetrazol-propanamide derivatives as novel CLEC-2 inhibitors. A total of 12 hit compounds also inhibited PDPN-induced platelet aggregation in humans and mice. Unexpectedly, these compounds also fit the collagen-binding pocket of the glycoprotein VI molecule, thereby inhibiting collagen interaction. These compounds also inhibited collagen-induced platelet aggregation, and one compound ameliorated collagen-induced thrombocytopenia in mice. For clinical use, these compounds will require a degree of chemical modification to decrease albumin binding.

Conclusion Nonetheless, as dual activation of platelets by collagen and PDPN-positive cells is expected to occur after the rupture of atherosclerotic plaques, these dual antagonists could represent a promising pharmacophore, particularly for arterial thrombosis, in addition to VTE and metastasis.

Keywords

tumor metastasis - thrombosis - stroke - myocardial infarction

Authors' Contribution

N.H. and S.I. conceived and planned the project. N.W., Y.S., S.O., and R.M. conducted the mouse experiments. N.W., A.S., Y.I., M.H., E.N., M.A., K.G., and Y.O. conducted in vitro experiments. J.K., Y.S., and N.F. conducted the electron microscopic analysis. N.H. conducted the molecular docking analysis. T.S. conducted the mass-spectrometry analysis. S.I. organized the project, and N.W., H.M., T.T., S.M., and Y.N. analyzed the data and wrote the manuscript. N.W. and S.I. edited the final manuscript. All authors have read and approved the final manuscript.


Supplementary Material



Publication History

Received: 09 March 2023

Accepted: 12 November 2023

Accepted Manuscript online:
15 November 2023

Article published online:
29 December 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Suzuki-Inoue K, Kato Y, Inoue O. et al. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem 2007; 282 (36) 25993-26001
    CrossrefPubMedGoogle Scholar
  • 2 Kato Y, Kaneko MK, Kunita A. et al. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci 2008; 99 (01) 54-61
    CrossrefPubMedGoogle Scholar
  • 3 Tanaka M, Kijima H, Shimada H, Makuuchi H, Ozawa S, Inokuchi S. Expression of podoplanin and vimentin is correlated with prognosis in esophageal squamous cell carcinoma. Mol Med Rep 2015; 12 (03) 4029-4036
    CrossrefPubMedGoogle Scholar
  • 4 Suzuki H, Kaneko MK, Kato Y. Roles of podoplanin in malignant progression of tumor. Cells 2022; 11 (03) 575
    CrossrefPubMedGoogle Scholar
  • 5 Kerrigan AM, Navarro-Nuñez L, Pyz E. et al. Podoplanin-expressing inflammatory macrophages activate murine platelets via CLEC-2. J Thromb Haemost 2012; 10 (03) 484-486
    CrossrefPubMedGoogle Scholar
  • 6 Hitchcock JR, Cook CN, Bobat S. et al. Inflammation drives thrombosis after Salmonella infection via CLEC-2 on platelets. J Clin Invest 2015; 125 (12) 4429-4446
    CrossrefPubMedGoogle Scholar
  • 7 Xie Z, Shao B, Hoover C. et al. Monocyte upregulation of podoplanin during early sepsis induces complement inhibitor release to protect liver function. JCI Insight 2020; 5 (13) e134749
    CrossrefPubMedGoogle Scholar
  • 8 Hatakeyama K, Kaneko MK, Kato Y. et al. Podoplanin expression in advanced atherosclerotic lesions of human aortas. Thromb Res 2012; 129 (04) e70-e76
    CrossrefPubMedGoogle Scholar
  • 9 Mir Seyed Nazari P, Riedl J, Pabinger I, Ay C. The role of podoplanin in cancer-associated thrombosis. Thromb Res 2018; 164 (Suppl 1): S34-S39
    CrossrefPubMedGoogle Scholar
  • 10 Suzuki-Inoue K. Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin. Blood 2019; 134 (22) 1912-1918
    CrossrefPubMedGoogle Scholar
  • 11 Mackman N, Bergmeier W, Stouffer GA, Weitz JI. Therapeutic strategies for thrombosis: new targets and approaches. Nat Rev Drug Discov 2020; 19 (05) 333-352
    CrossrefPubMedGoogle Scholar
  • 12 Induruwa I, Jung SM, Warburton EA. Beyond antiplatelets: the role of glycoprotein VI in ischemic stroke. Int J Stroke 2016; 11 (06) 618-625
    CrossrefPubMedGoogle Scholar
  • 13 Borst O, Gawaz M. Glycoprotein VI - novel target in antiplatelet medication. Pharmacol Ther 2021; 217: 107630
    CrossrefPubMedGoogle Scholar
  • 14 Watanabe N, Kidokoro M, Tanaka M. et al. Podoplanin is indispensable for cell motility and platelet-induced epithelial-to-mesenchymal transition-related gene expression in esophagus squamous carcinoma TE11A cells. Cancer Cell Int 2020; 20: 263
    CrossrefPubMedGoogle Scholar
  • 15 Watanabe N, Kidokoro M, Suzuki Y. et al. A pull-down and slot blot-based screening system for inhibitor compounds of the podoplanin-CLEC-2 interaction. PLoS One 2019; 14 (09) e0222331
    CrossrefPubMedGoogle Scholar
  • 16 Nagae M, Morita-Matsumoto K, Kato M, Kaneko MK, Kato Y, Yamaguchi Y. A platform of C-type lectin-like receptor CLEC-2 for binding O-glycosylated podoplanin and nonglycosylated rhodocytin. Structure 2014; 22 (12) 1711-1721
    CrossrefPubMedGoogle Scholar
  • 17 Molecular Operating Environment (MOE). , 2022.02 Chemical Computing Group ULC, 910-1010 Sherbrooke St. W., Montreal, QC H3A 2R7, Canada, 2023
    PubMed
  • 18 Goto J, Kataoka R, Muta H, Hirayama N. ASEDock-docking based on alpha spheres and excluded volumes. J Chem Inf Model 2008; 48 (03) 583-590
    CrossrefPubMedGoogle Scholar
  • 19 Chang YW, Hsieh PW, Chang YT. et al. Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis. Oncotarget 2015; 6 (40) 42733-42748
    CrossrefPubMedGoogle Scholar
  • 20 Suzuki-Inoue K, Fuller GL, García A. et al. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood 2006; 107 (02) 542-549
    CrossrefPubMedGoogle Scholar
  • 21 Dangelmaier C, Vari HR, Wright M, Kostyak JC, Kunapuli SP. Clustering extent-dependent differential signaling by CLEC-2 receptors in platelets. Res Pract Thromb Haemost 2022; 6 (03) e12710
    CrossrefPubMedGoogle Scholar
  • 22 Payne H, Ponomaryov T, Watson SP, Brill A. Mice with a deficiency in CLEC-2 are protected against deep vein thrombosis. Blood 2017; 129 (14) 2013-2020
    CrossrefPubMedGoogle Scholar
  • 23 Tsukiji N, Osada M, Sasaki T. et al. Cobalt hematoporphyrin inhibits CLEC-2-podoplanin interaction, tumor metastasis, and arterial/venous thrombosis in mice. Blood Adv 2018; 2 (17) 2214-2225
    CrossrefPubMedGoogle Scholar
  • 24 Lockyer S, Okuyama K, Begum S. et al. GPVI-deficient mice lack collagen responses and are protected against experimentally induced pulmonary thromboembolism. Thromb Res 2006; 118 (03) 371-380
    CrossrefPubMedGoogle Scholar
  • 25 Moroi M, Jung SM, Okuma M, Shinmyozu K. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J Clin Invest 1989; 84 (05) 1440-1445
    CrossrefPubMedGoogle Scholar
  • 26 Damaskinaki FN, Moran LA, Garcia A, Kellam B, Watson SP. Overcoming challenges in developing small molecule inhibitors for GPVI and CLEC-2. Platelets 2021; 32 (06) 744-752
    CrossrefPubMedGoogle Scholar
  • 27 Lebozec K, Jandrot-Perrus M, Avenard G, Favre-Bulle O, Billiald P. Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks. MAbs 2017; 9 (06) 945-958
    CrossrefPubMedGoogle Scholar
  • 28 Morán LA, Di Y, Sowa MA. et al. Katacine is a new ligand of CLEC-2 that acts as a platelet agonist. Thromb Haemost 2022; 122 (08) 1361-1368
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Miura Y, Takahashi T, Jung SM, Moroi M. Analysis of the interaction of platelet collagen receptor glycoprotein VI (GPVI) with collagen. A dimeric form of GPVI, but not the monomeric form, shows affinity to fibrous collagen. J Biol Chem 2002; 277 (48) 46197-46204
    CrossrefPubMedGoogle Scholar
  • 30 Massberg S, Konrad I, Bültmann A. et al. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J 2004; 18 (02) 397-399
    CrossrefPubMedGoogle Scholar
  • 31 Wichaiyo S, Svasti S, Supharattanasitthi W, Morales NP. Dasatinib induces loss of vascular integrity and promotes cutaneous wound repair in mice. J Thromb Haemost 2021; 19 (12) 3154-3167
    CrossrefPubMedGoogle Scholar
  • 32 Taylor L, Vasudevan SR, Jones CI. et al. Discovery of novel GPVI receptor antagonists by structure-based repurposing. PLoS One 2014; 9 (06) e101209
    CrossrefPubMedGoogle Scholar
  • 33 Onselaer MB, Nagy M, Pallini C. et al. Comparison of the GPVI inhibitors losartan and honokiol. Platelets 2020; 31 (02) 187-197
    CrossrefPubMedGoogle Scholar
  • 34 Montague SJ, Patel P, Martin EM. et al. Platelet activation by charged ligands and nanoparticles: platelet glycoprotein receptors as pattern recognition receptors. Platelets 2021; 32 (08) 1018-1030
    CrossrefPubMedGoogle Scholar
  • 35 Haji S, Ito T, Guenther C. et al. Human Dectin-1 is O-glycosylated and serves as a ligand for C-type lectin receptor CLEC-2. eLife 2022; 11: 11
    CrossrefPubMedGoogle Scholar
  • 36 Meng D, Luo M, Liu B. The role of CLEC-2 and its ligands in thromboinflammation. Front Immunol 2021; 12: 688643
    CrossrefPubMedGoogle Scholar
  • 37 Oishi S, Tsukiji N, Otake S. et al. Heme activates platelets and exacerbates rhabdomyolysis-induced acute kidney injury via CLEC-2 and GPVI/FcRγ. Blood Adv 2021; 5 (07) 2017-2026
    CrossrefPubMedGoogle Scholar
  • 38 Zhi Z, Jooss NJ, Sun Y. et al. Galectin-9 activates platelet ITAM receptors glycoprotein VI and C-type lectin-like receptor-2. J Thromb Haemost 2022; 20 (04) 936-950
    CrossrefPubMedGoogle Scholar
  • 39 Boulaftali Y, Hess PR, Getz TM. et al. Platelet ITAM signaling is critical for vascular integrity in inflammation. J Clin Invest 2013; 123 (02) 908-916
    PubMedGoogle Scholar
  • 40 Bender M, May F, Lorenz V. et al. Combined in vivo depletion of glycoprotein VI and C-type lectin-like receptor 2 severely compromises hemostasis and abrogates arterial thrombosis in mice. Arterioscler Thromb Vasc Biol 2013; 33 (05) 926-934
    CrossrefPubMedGoogle Scholar
  • 41 Lombard SE, Pollitt AY, Hughes CE. et al. Mouse podoplanin supports adhesion and aggregation of platelets under arterial shear: A novel mechanism of haemostasis. Platelets 2018; 29 (07) 716-722
    CrossrefPubMedGoogle Scholar
  • 42 Brown HC, Beck S, Navarro S. et al. Antibody-mediated depletion of human CLEC-2 in a novel humanised mouse model. . Blood Adv 2022
    PubMedGoogle Scholar